Drug Profile
Vixtimotamab - Affimed Therapeutics
Alternative Names: AMV-564; T-564; T-652Latest Information Update: 28 Oct 2022
Price :
$50
*
At a glance
- Originator Affimed Therapeutics
- Developer Amphivena Therapeutics
- Class Antineoplastics; Bispecific antibodies; Immunotherapies
- Mechanism of Action Antibody-dependent cell cytotoxicity; Cytotoxic T lymphocyte stimulants; Myeloid-derived suppressor cell inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Acute myeloid leukaemia; Myelodysplastic syndromes; Solid tumours
Most Recent Events
- 28 Oct 2022 No recent reports of development identified for phase-I development in Solid-tumours(Combination therapy, Inoperable/Unresectable, Late-stage disease, Metastatic disease, Second-line therapy or greater) in USA (SC, Injection)
- 28 Oct 2022 No recent reports of development identified for phase-I development in Solid-tumours(Inoperable/Unresectable, Late-stage disease, Metastatic disease, Monotherapy, Second-line therapy or greater) in USA (SC, Injection)
- 28 Jun 2022 No recent reports of development identified for phase-I development in Acute-myeloid-leukaemia(Combination therapy, Second-line therapy or greater) in USA (IV, Infusion)